Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H R Maecke

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II studyC Waldherr, M Pless, H R Maecke, et al.
Nuklearmedizin. Nuclear Medicine|August 21, 2018
Reply to: Appearances are often deceptiveC Boy, H Lahner, H R Maecke, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 15, 2000
Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogueC Waldherr, A Haldemann, H R Maecke, et al.
Anticancer Research|July 24, 2010
Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in ratsA Laznickova, M Laznicek, F Trejtnar, et al.
Lancet (London, England)|March 3, 1998
Yttrium-90-labelled somatostatin-analogue for cancer treatmentA Otte, J Mueller-Brand, S Dellas, et al.
Cancer Research|December 1, 1993
Preclinical evaluation of 67Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35A Smith, R Alberto, P Blaeuenstein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 1997
Tumor uptake and metabolism of copper-67-labeled monoclonal antibody chCE7 in nude mice bearing neuroblastoma xenograftsI Novak-Hofer, K Zimmermann, H R Maecke, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 16, 2004
A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumoursF Forrer, H Uusijärvi, C Waldherr, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 29, 2001
A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapyS Moll, V Nickeleit, J Mueller-Brand, et al.
European Journal of Nuclear Medicine|July 20, 2000
Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotideM Bangard, M Béhé, S Guhlke, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II studyC Waldherr, M Pless, H R Maecke, et al.
Nuklearmedizin. Nuclear Medicine|August 21, 2018
Reply to: Appearances are often deceptiveC Boy, H Lahner, H R Maecke, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 15, 2000
Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogueC Waldherr, A Haldemann, H R Maecke, et al.
Anticancer Research|July 24, 2010
Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in ratsA Laznickova, M Laznicek, F Trejtnar, et al.
Lancet (London, England)|March 3, 1998
Yttrium-90-labelled somatostatin-analogue for cancer treatmentA Otte, J Mueller-Brand, S Dellas, et al.
Cancer Research|December 1, 1993
Preclinical evaluation of 67Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35A Smith, R Alberto, P Blaeuenstein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 1997
Tumor uptake and metabolism of copper-67-labeled monoclonal antibody chCE7 in nude mice bearing neuroblastoma xenograftsI Novak-Hofer, K Zimmermann, H R Maecke, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 16, 2004
A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumoursF Forrer, H Uusijärvi, C Waldherr, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 29, 2001
A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapyS Moll, V Nickeleit, J Mueller-Brand, et al.
European Journal of Nuclear Medicine|July 20, 2000
Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotideM Bangard, M Béhé, S Guhlke, et al.
Pageof 4